Abbisko Medicine Co., Ltd. (HKG:2256)
Hong Kong · Delayed Price · Currency is HKD 6.33
+0.03 (0.40%)
Nov 10, 2026, 4:08 PM HKT
Abbisko Medicine Employees
Abbisko Medicine had 286 employees as of June 30, 2026. The number of employees increased by 10 or 3.62% since the number was reported on December 31, 2025. That makes Abbisko Medicine the 24,199th largest employer in the world and 1,562nd in Hong Kong.
Employees
286
Change
10
Growth
3.62%
Revenue / Employee
392.62K HKD
Profits / Employee
-1.88M HKD
Market Cap
4.19B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 286 | 10 | 3.62% |
| Dec 31, 2025 | 276 | -5 | -1.78% |
| Dec 31, 2024 | 281 | 23 | 8.91% |
| Dec 31, 2023 | 258 | 8 | 3.20% |
| Dec 31, 2022 | 250 | 90 | 56.25% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 1,925 |
| Lepu Biopharma | 646 |
| Ocumension Therapeutics | 608 |
| Qyuns Therapeutics | 353 |
| Mirxes Holding Company | 347 |
| Ascletis Pharma | 217 |
| Jacobio Pharmaceuticals Group | 207 |
| TransThera Sciences (Nanjing) | 132 |
Abbisko Medicine News
- 7 weeks ago - Abbisko's Lavengratinib Shows Early Growth Benefit In Children With Achondroplasia - Nasdaq
- 7 weeks ago - Abbisko's Lavengratinib Shows Early Height-Growth Benefit In Phase II Achondroplasia Study - Nasdaq
- 2 months ago - Abbisko Medicine Earnings release: H1 2026 - Filings
- 2 months ago - Abbisko Medicine Quarterly report: H1 2026 - Filings
- 4 months ago - Abbisko Therapeutics And AstraZeneca Enter Strategic Collaboration For Lumipodlin - Nasdaq
- 4 months ago - Abbisko Therapeutics Collaborates With Eli Lilly For Research And Development; Stock Up - Nasdaq
- 4 months ago - Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly - Reuters
- 8 months ago - Abbisko Medicine Earnings release: H2 2025 - Filings